IN
Inhibrx Biosciences Inc.
INBX · NASDAQ
$109.35 +3.58% (+$3.78)
1M +5.52%
Market Cap $1.54B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$155.09
41.8% upside
Trenutna cena
$109.35
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica INBX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
-
N/A P/FCF N/A
P/S N/A
P/B N/A
Growth
0 /100
Declining Book val. growth 48.36%
Rev. growth 15.98%
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 89.60%
Asset turnover 0.00x
ROIC 99.35%
Debt
43 /100
Moderate Int. coverage -7.88x
Current ratio 5.07x
Net debt/EBITDA N/A
Stability
1 /100
Unstable Rev. volatility 350.17%
EPS volatility 1,415.79%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o INBX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Lappe
Employees
110
Headquarters
La Jolla
Prihajajoči dogodki
13 NOV.
Earnings
Upcoming earnings report